Skip to content

Clinical Observation for TCM Combined Rehabilitation Therapy for Relieving Type 2 Diabetes Mellitus Based on the Thought of Regulating and Supplementing

Clinical Observation for TCM Combined Rehabilitation Therapy for Relieving Type 2 Diabetes Mellitus Based on the Thought of Regulating and Supplementing

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023400
Enrollment
Unknown
Registered
2019-05-25
Start date
2019-05-27
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Sponsors

Dongzhimen Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged 18-75 years old; (2) Clinically diagnosed with Type 2 diabetes mellitus with a course of less than 8 years. Fasting blood glucose < 7 mmol/L and HbA1c < 7% after drug intervention. (3) Presently receiving Western medicine treatment (with unlimited varieties and methods of medication). (4) The C-peptide levels of T2DM patients receiving insulin treatment should be greater than or equal to 0.2 nmol/L (0.6 ng/mL); (5) BMI < 28 kg/m2; (6) Systolic blood pressure < 160 mmHg and diastolic blood pressure < 100 mmHg in patients with hypertension(after medication intervention); (7) Being able to follow the treatment, examination and follow-up plan; (8) Fully understand and voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Obvious abnormal liver and kidney function (more than 2 times of normal value); (2) Alcoholism, malignant tumors, epilepsy or mental disorders; (3) Type 1 diabetes; (4) Serious diabetic complications; (5) Arrhythmia, cardiopulmonary disfunction or previous stent surgery; (6) With a pacemaker, hearing aid or other electronic or metal components; (7) Severe infections, infectious diseases and severe skin lesions; (8) Pregnant women, pregnancy preparation or lactating women; (9) Weight-loss surgery or gastrointestinal surgery; (10) Severe pathological changes of gallbladder, thyroid, kidney and other tissues or organs after operation; (11) Clinically diagnosed peptic ulcer; (12) Participating in other clinical studies; (13) Other reasons that can not cooperate with the study.

Design outcomes

Primary

MeasureTime frame
HbA1c;pancreatic islet function;Withdrawal rate of antidiabetic agents;

Secondary

MeasureTime frame
fasting blood glucose;2 h postprandial blood glucose;HbA1c;Withdrawal rate of antidiabetic agents;SF-36 Health Survey;EuroQol five dimensions questionnaire;Diabetes Specific Quality of Life Scale,DSQL;

Countries

China

Contacts

Public ContactGuoyong Yu

Dongzhimen Hospital of Beijing University of Chinese Medicine

18901133535@163.com+86 18901133535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026